* Forte Biosciences Inc FBRX.OQ FBRX.O is expected to report
results on May 10.
* Refinitiv's mean analyst estimate for Forte Biosciences Inc
is for a loss of 52 cents per share. For the same quarter last
year, the company reported a loss of $6.45 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Forte
Biosciences Inc is $90, about 64.4% above its last closing
price of $32.00.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Dec. 31 2020 -0.57 -0.37 Beat 35.5
Sep. 30 2020 -0.54 -0.54 -0.45 Beat 16.7
Jun. 30 2020 -0.19 -0.19 -9.52 Missed -4,910
.5
Mar. 31 2020 -6.60 -6.45 Beat 2.3
Dec. -8.58 -8.55 -7.50 Beat 12.3
31 2019
Sep. 30 2019 -10.33 -10.49 -11.70 Missed -11.5
Jun. 30 2019 -11.26 -11.34 -10.80 Beat 4.8
Mar. 31 2019 -16.86 -15.15 -11.10 Beat 26.7
This summary was machine generated May 7 at 21:10 GMT. All
figures in US dollars unless otherwise stated